Navigation Links
Schering-Plough Announces Planned Divestiture of Select Animal Health Products in Europe
Date:4/23/2008

KENILWORTH, N.J., April 23 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced two agreements to divest animal health products from 12 product franchises in Europe. These agreements are in connection with conditions set forth by the European Commission as part of its October 2007 clearance of Schering-Plough's acquisition of the Intervet animal health business from Akzo Nobel N.V.

In two separate agreements, Pfizer and Virbac, a French animal health company, will acquire the 12 product franchises. Pfizer will acquire products from Schering-Plough's parasiticide, swine E. coli vaccine, ruminant clostridia vaccine, equine influenza vaccine, ruminant neonatal vaccine, anti-inflammatory, companion animal/insulin and companion animal/euthanasia, and rabies vaccine franchises. Virbac will acquire products from Schering-Plough's endocrine, mastitis and sulphonamide franchises. The agreements do not affect Schering-Plough's marketing of these products in other global markets. No manufacturing facilities or employees will be transferred with these products. Schering-Plough will supply product to both Pfizer and Virbac with oversight from a monitoring trustee for a contractually defined period of time. The transactions are subject to certain closing conditions, including regulatory approval by the European Commission.

DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the divestiture of certain animal health products. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces; economic factors; and the regulatory process; , among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Part I, Item IA. "Risk Factors" in Schering-Plough's 2007 10-K/A.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Schering-Plough Reports Financial Results for First Quarter of 2008
2. Schering-Plough Schedules Conference Call and Webcast for 2008 First Quarter Earnings
3. Schering-Plough Launches Productivity Transformation Program To Confront New Challenges
4. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
5. Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R)
6. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
7. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
8. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
9. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
10. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
11. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2016)... , May 18, 2016 ... 2.0 prefilled pen following approval by EMA, the European ... leading science and technology company, the new pen version ... an increased level of confidence to patients during use. ... GONAL-f® prefilled pen easier to handle with a larger ...
(Date:5/17/2016)... ... May 17, 2016 , ... PATH and Laerdal ... collaborate to bring a feeding cup to market based on a reference design ... Center at Seattle Children’s Hospital, thereby ensuring an innovative feeding option for the ...
(Date:5/17/2016)... ... , ... A new study on mesothelioma trends in Sweden indicates that there ... Mesothelioma has just posted an article on the new research. Click here to ... kidney cancer seem to be more susceptible to mesothelioma, the researchers still aren’t sure ...
(Date:5/17/2016)... ... May 17, 2016 , ... New tests that go beyond the standard ... specific information that both the patient and doctor want and need to know in ... the American Urological Association’s annual meeting in San Diego, involve using blood, urine and ...
Breaking Biology Technology:
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
(Date:3/23/2016)... Massachusetts , March 23, 2016 /PRNewswire/ ... im Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung ... Xura, Inc. (NASDAQ: MESG ), ... bekannt, dass das Unternehmen mit SpeechPro zusammenarbeitet, ... aus der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, ...
(Date:3/17/2016)... 17, 2016 ABI Research, the leader ... global biometrics market will reach more than $30 ... from 2015. Consumer electronics, particularly smartphones, continue to ... anticipated to reach two billion shipments by 2021 ... Pavlakis , Research Analyst at ABI Research. "Surveillance ...
Breaking Biology News(10 mins):